Immunotherapy before liver surgery for early-stage liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving an immunotherapy drug (atezolizumab) before liver surgery can help your immune system fight liver cancer more effectively. You would receive the drug before your planned surgery, and the study will compare your outcomes with those who have surgery alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 or older).
- You must be scheduled for surgery to remove part of your liver (liver resection) for liver cancer.
- Your liver cancer must be at a very early or early stage, and you must be in good enough health to have surgery.
- You must not have had any severe allergic reactions to immunotherapy in the past.
- You must not be currently taking steroid medications (like prednisone).
- You must not be pregnant or breastfeeding, and if you can get pregnant, you must use contraception during the study and for 5 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach: giving two immunotherapy drugs (sintilimab and ipilimumab) along with treatments that block blood flow to the tumor (TACE or ablation) before surgery for liver cancer that is at high risk of coming back. The goal is to see if this combination can shrink the tumor and reduce the chance of recurrence after surgery.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests whether giving a combination of two immunotherapy drugs before a liver transplant can help people with advanced liver cancer (beyond standard size limits) receive a transplant successfully. The treatment aims to shrink the tumor and improve outcomes.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.